Study 12 of 13LL-37 literatureScience (New York, N.Y.)Top journal2026
A rocky rollout.
Not reported in abstract.
Where it sits
this study against the rest of the ll-37 corpus5
Preclinical · this one
4
Observational
0
Open-label
2
Randomised
2
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the LL-37 corpus
AAdonertinib (FHND9041) versus Afatinib as First-line Treatment for Advanced Non-small-cell Lung Cancer with EGFR Sensitive Mutation (FHND9041-Ⅲ-01): A Multi-centre, Open-label, Randomised Phase 3 Trialbiorxiv-preprint · Median PFS was 16.7 months in the adonertinib group and 14.5 months in the afatinib group (HR 0.70, p=0.0087).HumanBThe interplay between vitamin D status and exerkine signaling: implications for exercise adaptation in athletes: narrative review.Journal of the International Society of Sports Nutrition · 2026HumanBPatterns of health-promoting lifestyles among patients with colorectal cancer: A latent profile analysis.Asia-Pacific journal of oncology nursing · 2026 · Profile 2 associated with psychological frailty (OR = 1.799, P = 0.001)HumanAImmunogenicity and safety of AS03-adjuvanted A/Astrakhan/3212/2020 (H5N8)-like influenza vaccine in adults: Phase 1/2, observer-blinded, randomized trial.Human vaccines & immunotherapeutics · 2026 · Not reported in abstract.HumanBFrom childhood to adult trauma and negative birth experiences: distal and proximal factors associated with childbirth-related posttraumatic stress symptoms.European journal of psychotraumatology · 2026 · CM significantly predicted higher levels of childbirth-related intrusion symptoms, p<0.01.HumanAEndometriosis and cardiovascular disease risk: a meta-analysis of cohort studies.Annals of medicine · 2025 · HR = 1.22; 95% CI: 1.08-1.38; I2 = 94.6% for all-cause CVD.Human